ArticleSchizophrenia (Heidelberg, Germany)2026
Integrated alterations in inflammation, endothelial function, and extracellular matrix pathways in first-episode drug-naïve schizophrenia.
Article in Schizophrenia (Heidelberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective peripheral biomarkers for early-stage schizophrenia are needed to improve diagnostic accuracy and treatment planning. To identify potential biomarkers, we compared multiple serum factor concentrations between 90 first-episode drug-naïve patients and healthy matched controls, and further examined associations with symptom severity and cognitive functions among patients. Serum interleukin (IL)-8, vascular cell adhesion molecule (VCAM)-1, matrix metalloproteinase (MMP)-2, and MMP-7 concentrations were quantified by Luminex multiplex immunoassays, and log10-transformed values compared with adjustment for age, sex, years of education, body mass index, and smoking status. Associations with symptoms as assessed by the Positive and Negative Syndrome Scale (PANSS) and cognitive functions as assessed by the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) were examined by Pearson's correlation analysis. Multivariable logistic regression models were developed for case-control discrimination by receiver operating characteristic analysis with 10-fold cross-validation and calibration. Serum log10[IL-8] and log10[MMP-7] were higher while serum log10[MMP-2] and log10[VCAM-1] were lower in patients. Serum log10[MMP-2], log10[MMP-7], and log10[VCAM-1] were positively correlated among patients, whereas log10[IL-8] was not associated with this MMP/VCAM-1 axis. There were no stable linear associations with PANSS or RBANS scores. Serum log10[IL-8] demonstrated the highest single-marker discrimination (AUC = 0.742, 95%CI: 0.667-0.817), and the four-biomarker model further improved discrimination (AUC = 0.839, 95%CI: 0.781-0.897; 10-fold cross-validated AUC = 0.804). A Youden-derived threshold of 0.518 yielded 78.9% sensitivity and specificity for distinguishing cases. A serum inflammation-endothelium-extracellular matrix biomarker panel showed good discriminative performance in distinguishing first-episode drug-naïve schizophrenia from controls in a case-control sample; external validation and potential recalibration in real-world cohorts are warranted.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.